|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets
Datamonitor, Aug 2002
Leukemia incorporates a wide range of histologically distinct disorders. Despite the high level of unmet need associated with the disease and its reliance on chemotherapy, historically, leukemia has not been the focus of significant R&D investment for the pharmaceutical industry. The launch of Novartis’ second-line therapy Gleevec (imatinib mesylate) for Chronic myeloid leukemia (CML), is presenting the industry with proof that development within the leukemia market produces lucrative returns.Key therapeutic areas investigated are the chronic and acute leukemias: CLL, CML, ALL, Amlmarketing and development strategies are analyzed and forecast, covering both the biotechnology sector and the large pharmaceutical sectorOverview of the key drugs in drugs in Phase III and II developmentComprehensive analysis of key late-stage products, with Datamonitor forecasts of drug revenues to 2010Despite the size limitations of the leukemia patient population, the high levels of unmet need in the leukemias lends itself to an attractive market for drug therapy development, with the potential for accelerated approvals and premium pricing as key merits.Find out why the leukemia market, previously not a major focus in the industry, looks set to grow rapidly over the next decadeIdentify existing unmet needs, and see how current developmental products seek to address themFollow the development of innovative pharmacotherapies, and their potential impact on traditional therapies
Customers who bought this item also bought
Leukemia - A Therapeutic & Competitive Insight
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report
Analytical Tool - Leukemia Therapeutics & Competitive Insights
Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Chinese Markets for Leukemia Treatment Drugs
Acute Myeloid Leukemia: Cytarabine Here to Stay
Br. Holdings Corporation
Br Malls Participacoes Sa
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
|
|
|
|
